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Abstract
Background: Asymptomatic ventricular arrhythmias are common and associated with increased risk of
cardiovascular mortality. Cardiac troponins, natriuretic peptides and C–reactive protein (CRP) are also predictive of
adverse cardiovascular events in the general population, but limited information is available on the relationship
between these biomarkers and ventricular ectopy in a community-based population.
The objectives were to evaluate the associations between ventricular ectopic activity and N-terminal pro-B-type
natriuretic peptide (NT-proBNP), high sensitivity-troponin I (hs-TnI) and hs-CRP in a community-based setting.
Methods: We performed a 24 h Holter-recording and blood sampling in 498 subjects. Premature ventricular
complexes (PVC) were classified as frequent at >5/h and the presence of any bigeminy, trigeminy or non-sustained
ventricular tachycardia were classified as complex ventricular ectopy. The associations between biomarkers and
ventricular arrhythmias were investigated by univariate and multivariate logistic regression analyses.
Results: Frequent PVC’s and complex ventricular ectopy were detected in 46 (9%) and 47 (9%) participants
respectively, and were associated with significantly (p < 0.001) higher concentrations of NT-proBNP and hs-TnI. The
association between NT-proBNP and both frequent PVC’s (p = 0.020) and complex ventricular ectopy (p = 0.001)
remained significant after adjusting for conventional risk markers in multivariate analyses.
Conclusion: Increased level of NT-proBNP was independently associated with ventricular ectopy, whereas no
independent association was observed between hs-TnI and hs-CRP levels and ventricular ectopy in this community-
based sample.
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Background
Cardiovascular (CV) biomarkers play an increasingly
important role in the diagnosis of cardiac diseases, in-
cluding the use of cardiac troponins to diagnose acute
myocardial infarction [1] and B-type natriuretic peptide
(BNP) and N-terminal (NT)-proBNP to diagnose heart
failure (HF) [2]. Recently, high sensitivity (hs) assays for
determination of very low levels of circulating troponins
have been developed [3], and we and others have
demonstrated that hs cardiac troponin I (hs-TnI) and T
(hs-TnT) levels are predictive of adverse cardiovascular
events in patients with stable coronary artery disease
[4, 5], as well as in community-based cohorts [6, 7].
Likewise, BNP and NT-proBNP concentrations are
strongly associated with cardiovascular risk in the
general population [8] and low-level increments of C-
reactive protein (CRP), as measured by high-sensitive
assays, also predict risk in patients at low or moder-
ate risk for coronary heart disease (CHD) [9, 10].
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Sudden cardiac death, often caused by ventricular ar-
rhythmias, is a common cause of death both in patients
with established CHD, as well as in the general popula-
tion [11–13]. Asymptomatic ventricular arrhythmias
are commonly observed in community-based samples
[14], and have in some studies been linked to increased
risk of sudden cardiac death and death from cardiovas-
cular causes [15, 16]. As the established CV biomarkers
are associated with mortality in the general population,
these biomarkers may also predict asymptomatic ven-
tricular arrhythmias in the general population. How-
ever, currently only sparse data are available concerning
the association between CV biomarkers and the fre-
quency of arrhythmias in community-based cohorts
[17]. Accordingly, the objective of the current study
was to assess the potential associations between the
concentrations of hs-TnI, NT-proBNP and hs-CRP and




This is a substudy of the Akershus Sleep Apnea Pro-
ject (ASAP), which is a community-based, cross-
sectional study conducted in south Eastern Norway. In
a two-phased design, we first randomly drew 30 000
persons between 30 and 65 years of age from the Na-
tional Population Register (Fig. 1). All participants
received the Berlin Questionnaire, a standardized
questionnaire for classifying the risk for obstructive sleep
apnea (OSA) [18], by mail. Of the 16302 (55.7%) re-
sponders, 1772 persons were randomly drawn as a pool
for inclusion in phase 2. A 2:1 ratio of high risk:low risk
participants according to the Berlin questionnaire in the
Phase 2 clinical sample resulted in oversampling of partic-
ipants with risk factors for obstructive sleep apnea, i.e.
snoring, daytime sleepiness, obesity and hypertension. In
addition, persons with previous CHD, otitis media surgery
or diabetes were oversampled. Predefined age-dependent
strata were made to ensure gender equilibrium and a 2:1
ratio of high risk:low risk participants according to the
Berlin Questionnaire. Invitations were made by telephone,
and 585 of the invited refused to participate, 202 were not
reached after three attempts, and 28 persons were
excluded. Exclusion criteria of the study included use of
continuous positive airway pressure, physical impairment,
pregnancy and insufficient Norwegian language skills. In
the end, 535 (46.7% of the contacted) persons participated
in the clinical phase of the study, while 442 persons from
the pool of 1772 were not contacted as the predefined
strata were completed. Further details of the recruitment
protocol have been described previously [19].
Data collection
All participants (n = 535) arrived at noon and stayed
over-night at Akershus University Hospital, Stensby
where collection of all of the data was performed.
Blood sampling and analysis
Fasting blood samples were collected from an antecubi-
tal vein in the morning, and were centrifuged within one
hour. Serum samples were stored at – 20°C for a max-
imum of 20 days, before they were transported to the
central biobank and frozen at −80°C pending later mea-
surements. Sampling and storing failed for 4 partici-
pants. hs-TnI was measured using the ARCHITECT
STAT hs Troponin assay (Abbott Diagnostics, Illinois,
USA) as previously reported [20]. NT-proBNP was mea-
sured by electrochemiluminescent immunoassay (Roche
Diagnostics, Basel, Switzerland) with a lower detection
limit of 5 pg/ml. The hs-CRP measurements were
performed using a latex immunoassay kit on a COBAS
INTEGRA400 (Roche Diagnostics, Basel, Switzerland),
with a lower detection limit of 0.1 pg/mL. Analyses of
biomarkers were not performed for 9 participants due to
lack of available plasma. Creatinine, glucose and lipids
were measured by standard laboratory methods. The
creatinine clearance was estimated by the Cockcroft-
Gault formula [21].
Electrocardiography
All participants underwent an in-hospital 5-channel ambu-
latory electrocardiography (Medilog AR12, Oxford Instru-
ments Medical, Surrey, United Kingdom) for assessment of
cardiac arrhythmias. Recordings with a shorter duration
than 10 h, or with technical failure, were excluded from
the analysis (n = 10). The mean length of the recordings
was 18.3 h. The electrocardiography recordings were
Fig. 1 Flow-diagram of the inclusion procedure in Akershus Sleep
Apnea Project, and participants in the present substudy
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automatically analyzed by a software engine (Medilog
Darwin, ScanMed Medical, Gloucestershire, United
Kingdom) according to predefined criteria. A prema-
ture ventricular complex (PVC) was defined as a N-V
complex >15% shorter than the previous 3 N-N com-
plexes. All PVC’s were counted and dichotomized at a
cut off of 5/h. We defined complex ventricular ectopy
as any bigeminy (≥3 consecutive V-N complexes),
trigeminy (≥3 consecutive V-N-N complexes), or non-
sustained ventricular tachycardia (≥3 consecutive V
complexes). One researcher, blinded for the partici-
pants’ medical background and biomarker levels,
manually reviewed and re-scored all recordings. A
second researcher manually reviewed 10% of the re-
cordings. The inter-rater correlation was 0.99. Exam-
ples of frequent PVC and complex ventricular ectopy
are shown in Fig. 2.
Demographic variables and cardiovascular risk factors
The participants were asked about history of CHD (myo-
cardial infarction or coronary artery revascularization),
history of congestive heart failure, use of antihypertensive
medication, diabetes mellitus and current smoking habits
and underwent a standard physical examination. Blood
pressure was measured in the sitting position after 15 min
rest by an automatic device (Dinamap, ProCare 400, GE
HealthCare, Milwaukee, WI, USA). The mean of the two
last out of three recordings was calculated and used
in analysis. The Sokolow-Lyon criteria were used for
estimation of left ventricle hypertrophy [22]. Body
mass index (weight in kg/ height in meters squared)
was calculated. The participants underwent in-
hospital polysomnography, as previously reported
[19]. Data were manually scored using the Somnolo-
gica 3.2 software (Flaga-Medcare, Buffalo, New York),
13 registrations were not analyzed due to technical
failure or short sleep duration. The apnea-hypopnea
index (AHI) was calculated using the average number
of apneas (airflow <10% of reference in more than
10s) plus hypopneas (airflow <30% in more than 10s
and subsequent ≥4% fall in oxygen saturation) per
hour of sleep.
Fig. 2 Examples of premature ventricular contraction (PVC) and complex ventricular ectopy
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Statistical analysis
Due to skewed distribution of data, we transformed NT-
proBNP, hs-TnI, CRP and AHI concentrations logarith-
mically prior to the analysis. Categorical data are pre-
sented as absolute numbers and percentages, continuous
data as mean (standard deviation) or median (interquar-
tile range). The associations between biomarkers and
ventricular arrhythmias were investigated by univariate
and multivariate logistic regression analyses. According
to a previous report from the same study, OSA may be
associated with increased risk of PVC’s [23], conse-
quently we included the AHI as covariate in addition to
the conventional cardiovascular risk factors (age, gender,
history of CHD, history of diabetes, history of hyperten-
sion, body mass index, systolic blood pressure, total
cholesterol:HDL cholesterol ratio). Covariates signifi-
cantly (p < 0.05) associated with arrhythmias in univari-
ate analyses were first entered into multivariate models.
The cardiovascular biomarkers were subsequently added
to make separate multivariate models to evaluate
whether hs-TnI, NT-proBNP or hs-CRP added signifi-
cant incremental information to the regression models.
The results are reported as odds ratio (OR) and 95% confi-
dence intervals (CI) and a p value (2-sided) < 0.05 was
considered statistically significant for all analyses. All stat-
istical analyses were performed with the SPSS statistical
software package, version 20 (SPSS Inc., Chicago, USA).
Results
Patient characteristics
A total of 498 participants had a complete data set in this
substudy. More than 5 PVC/h were observed in 46 partici-
pants (9%), while non-sustained ventricular arrhythmia,
bigeminy and trigeminy were observed in 13, 26 and 27
participants, respectively. As 19 persons had more than
Table 2 Demographic and clinical characteristics in patients with and without complex ventricular ectopy
No complex n = 455 Any complex n = 47 OR (95% CI) P
Age (mean, SD) 48 (11) 56 (9) 1.08 (1.05, 1.11) <0.001
Male gender (n, %) 249 (55) 26 (55) 1.09 (0.66, 1.79) 0.752
Current smoking (n, %) 121 (27) 11 (23) 0.84 (0.47, 1.50) 0.552
History of coronary artery disease (n, %) 38 (8) 12 (26) 3.65 (1.91, 6.96) <0.001
History of hypertension (n, %) 144 (32) 20 (43) 1.96 (1.18, 3.26) 0.009
Diabetes mellitus (n, %) 57 (13) 3 (6) 0.92 (0.42, 2.03) 0.838
Creatinine clearance (mean, SD) 125 (36) 118 (33) 0.99 (0.99, 1.00) 0.062
Systolic blood pressure, mm Hg (mean, SD) 134 (18) 145 (20) 1.02 (1.01, 1.04) 0.003
Body mass index (mean, SD) 29 (5) 30 (6) 1.01 (0.97, 1.07) 0.597
Cholesterol ratio (mean, SD) 4.5 (2.6) 4.3 (1.4) 0.94 (0.79, 1.12) 0.474
Left ventricular hypertrophy (n, %) 23 (5) 3 (6) 2.35 (0.95, 5.80) 0.065
AHI (median, Q 1–3) 5.9 (1.6, 17.1) 12.1 (6.0, 36.0) 1.42 (1.18, 1.72) <0.001
AHI apnea-hypopnea index, CI confidence interval, OR odds ratio, Q quartiles, SD standard deviation
Table 1 Demographic and clinical characteristics in patients with and without > 5 PVC/h
<5 PVC/h n = 452 >5 PVC/h n = 46 OR (95% CI) P
Age (mean, SD) 48 (11) 56 (9) 1.09 (1.05–1.12) <0.001
Male gender (n, %) 243 (54) 29 (63) 1.47 (0.78–2.75) 0.230
Current smoking (n, %) 121 (27) 11 (25) 0.89 (0.44–1.81) 0.742
History of coronary artery disease (n, %) 37 (8) 13 (28) 4.42 (2.14–9.12) <0.001
History of hypertension (n, %) 137 (30) 24 (52) 2.51 (1.36–4.62) 0.003
Diabetes mellitus (n, %) 52 (12) 7 (15) 1.38 (0.59–3.25) 0.460
Creatinine clearance (mean, SD) 124 (37) 119 (32) 1.00 (0.99–1.01) 0.363
Systolic blood pressure, mm Hg (mean, SD) 135 (18) 136 (16) 1.00 (0.99–1.02) 0.673
Body mass index (mean, SD) 28.8 (5.0) 29.2 (4.8) 1.02 (0.96–1.08) 0.590
Cholesterol ratio (mean, SD) 4.5 (2.6) 4.3 (1.3) 0.93 (0.74–1.15) 0.490
Left ventricular hypertrophy (n, %) 27 (6) 7 (15) 2.81 (1.15–6.87) 0.023
AHI (median, Q 1–3) 5.7 (1.5–16.9) 12.4 (6.9–40.6) 1.65 (1.30–2.09) <0.001
AHI apnea-hypopnea index, CI confidence interval, OR odds ratio, PVC premature ventricular complexes, Q quartiles, SD standard deviation
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one type of complex ventricular ectopy, a total number of
47 persons (9%) had any complex ventricular ectopy.
Demographic and clinical characteristics according to
the presence or absence of more than 5 PVC/h or any
complex ventricular arrhythmia are summarized in Tables 1
and 2. No patients reported congestive heart failure.
Association between biomarkers and ventricular
arrhythmias
We found higher concentrations of hs-TnI (3.0 vs. 1.4 ng/
L, p < 0.001) and NT-proBNP (75.7 vs. 41.3 pg/mL, p <
0.001) among the participants who had >5 PVC/h (Fig. 2).
In contrast, hs-CRP concentrations did not differ between
the two groups (1.0 vs. 1.2 mg/L, p = 0.978). The concen-
trations of hs-TnI (3.0 vs. 1.4 ng/L, p < 0.001) and NT-
proBNP (82.6 vs. 41.0 pg/mL, p < 0.001) were also higher
among participants with complex ventricular ectopy com-
pared to those without, while we found no difference for
hs-CRP concentrations (1.1 vs. 1.2 mg/L, p = 0.58) (Fig. 3).
Age, history of CHD, history of hypertension, left
ventricular hypertrophy and AHI were associated with
frequent PVC’s and included in the multivariate models
(Table 3, Model 1). Each of the biomarkers hs-TnI
(Model 2), NT-proBNP (Model 3) and hs-CRP (Model 4),
was then added to the variables included in Model 1. The
association between NT-proBNP and >5 PVC/h remained
significant (OR 1.50 [95% CI 1.07–2.12], p = 0.020) in
multivariate analyses, while the association between
frequent PVC and hs-TnI was attenuated. NT-proBNP
was also significantly associated with complex ventricular
ectopy in analysis (OR 1.81 [1.27–2.57], p = 0.001) that ad-
justed for age, history of CHD, systolic blood pressure and
AHI. The association between complex ventricular ectopy
and hs-TnI was attenuated and no longer statistical
significant in multivariate analyses (Table 4).
Discussion
The main finding of the current study is that higher
levels of NT-proBNP, but not hs-TnI or hs-CRP levels,
are independently associated with the incidence of fre-
quent ventricular ectopy and complex ventricular ectopy
in a moderately large, community-based study population.
The present study assessed the relationship between
two types of biomarkers for future CVD; low-level incre-
ments in circulating biomarkers and asymptomatic ven-
tricular arrhythmias. We are aware of only one prior
community-based study that reported higher unadjusted
concentrations of NT-proBNP and CRP in persons with
frequent PVC [17]. In that study, the combination of
elevated CRP and frequent PVC increased the risk for
future cardiovascular events, while NT-proBNP levels
did not affect the association between frequent PVC and
the outcomes. However, to the best of our knowledge,
the associations between serum biomarkers and complex
ventricular ectopy as well as the association between
cardiac troponins and asymptomatic ventricular arrhyth-
mias, have not previously been studied. We report that
the concentration of NT-proBNP is associated with
increased risk for both frequent PVCs and complex
ventricular arrhythmias such as non-sustained ventricu-
lar tachycardias, bigeminy and trigeminy, independent of
traditional risk factors for CVD. Regarding hs-TnI, the
increase in serum concentration observed in partici-
pants with ventricular ectopy was not significant after
Fig. 3 Serum-concentrations of biomarkers in 498 participants
according to the presence or absence of frequent PVCs or complex
ventricular ectopy
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adjustment for established hypertension, CHD, ECG-
calculated left ventricular hypertrophy and AHI. In
contrast to Sajadieh et al., we found no association
between the inflammatory marker hs-CRP and any
type of ventricular arrhythmia.
Different mechanisms may account for the association
between NT-proBNP and ventricular arrhythmias. Left
ventricular hypertrophy and mild left ventricular dys-
function are important determinants of low-level incre-
ments of both NT-proBNP and cardiac troponins [6],
and are also associated with the risk of arrhythmias.
Sub-clinical myocardial scarring and diffuse fibrosis may
also cause both increased levels of cardiac markers as
well as substrates for ventricular arrhythmias [24]. In
contrast, subclinical myocardial inflammation, at least as
reflected by hs-CRP concentrations, did not explain the
tendency toward ventricular arrhythmias in our
community-based cohort of relatively young subjects.
The increase of circulating NT-proBNP could also be a
result of the arrhythmia itself. However, as the observed
arrhythmias were short-lasting and asymptomatic in this
study, we find it unlikely that the arrhythmia itself has
increased the NT-proBNP concentrations. Finally, recent
data from the ASAP study suggest that the severity of
OSA, as expressed by the AHI, could be independently
associated with both asymptomatic arrhythmias [23] and
troponin I [25]. At the time of preparation of the previ-
ous manuscript regarding frequent PVC’s, data concern-
ing troponin I and NT-proBNP were not available, but
the present data suggest that, at least for NT-proBNP,
AHI is not the underlying mechanism.
A strength of this study is the community-based de-
sign and sample size. The generalizability is limited by
the inclusion procedure, biasing participants with high
weight, hypertension, snoring and daytime sleepiness.
Thus, the risk factor profile current cohort is not reflect-
ive of the general population. Statistic procedures have
been made to adjust for the presence of sleep apnea and
CV risk factors. The lack of echocardiographic measures,
particularly of left ventricular function, is another limita-
tion of this study. Cardiac imaging data could potentially
have added further information to the analysis; however,
we included electrocardiographic signs of left ventricular
hypertrophy in the study.
Table 3 Statistical significant determinants of >5 PVC/h, separate models for the 3 cardiovascular biomarkers. Multivariate logistic










Age 1.07 (1.03–1.11) 0.001 1.06 (1.02–1.11) 0.005 1.05 (1.01–1.10) 0.014 1.07 (1.03–1.11) 0.001
History of coronary heart disease 2.80 (1.17–6.76) 0.021 2.52 (1.03–6.19) 0.044 2.00 (0.77–5.15) 0.152 2.76 (1.14–6.70) 0.025
History of hypertension 0.76 (0.34–1.66) 0.486 0.76 (0.34–1.67) 0.489 0.76 (0.34–1.68) 0.491 0.77 (0.45–1.70) 0.511
AHI (events/h) 1.41 (1.08–1.83) 0.010 1.37 (1.05–1.78) 0.019 1.46 (1.12–1.90) 0.006 1.42 (1.09–1.85) 0.010
Left ventricular hypertrophy 2.84 (1.07–7.57) 0.037 2.69 (1.00–7.26) 0.051 3.06 (1.13–8.32) 0.028 2.82 (1.06–7.53) 0.039
log hs-CRP (mg/L) 0.96 (0.69–1.33) 0.785
log NT-proBNP (pg/mL) 1.50 (1.07–2.12) 0.020
log hs-TnI (ng/L) 1.32 (0.86–2.03) 0.205
hs-CRP, NT-proBNP and hs-TnI were transformed by logarithm before regression analysis
AHI apnea-hypopnea index, CI confidence interval, hsCRP high-sensitive C-reactive protein, hs-TnI high-sensitive cardiac Troponin I, NT-proBNP N-terminal
proB-type natriuretic peptide, OR odds ratio, PVC premature ventricular complexes
Table 4 Statistical significant determinants of complex ventricular ectopy, separate models for the 3 cardiovascular biomarkers.










Age 1.06 (1.02–1.10) 0.003 1.06 (1.02–1.10) 0.007 1.04 (0.99–1.08) 0.091 1.06 (1.02–1.10) 0.003
History of coronary artery disease 2.48 (1.14–5.39) 0.022 2.29 (1.02–5.14) 0.044 1.49 (0.63–3.56) 0.365 2.50 (1.14–5.46) 0.022
Systolic blood pressure (mmHg) 1.02 (1.00–1.04) 0.033 1.02 (1.00–1.04) 0.057 1.02 (1.00–1.04) 0.037 1.02 (1.00–1.04) 0.034
AHI (events/h) 1.20 (0.95–1.51) 0.130 1.18 (0.93–1.50) 0.165 1.25 (0.98–1.58) 0.072 1.19 (0.94–1.51) 0.149
log hs-CRP (mg/L) 1.04 (0.76–1.44) 0.801
log NT-proBNP (pg/mL) 1.81 (1.27–2.57) 0.001
log hs-TnI (ng/L) 1.18 (0.76–1.81) 0.467
hs-CRP, NT-proBNP and hs-TnI were transformed by logarithm before regression analysis
AHI apnea-hypopnea index, CI confidence interval, hs-CRP high-sensitive C-reactive protein, hs-TnI high-sensitive cardiac Troponin I, NT-proBNP N-terminal
proB-type natriuretic peptide, OR odds ratio
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It is debated whether ventricular ectopy is an inde-
pendent risk marker of mortality. In patients with estab-
lished cardiac disease, the association may be explained
by other established risk factors [26], while a recent
report from a community-based study suggests that
PVC’s predict HF and mortality [27]. The current study
indicates that circulating biomarkers that assess low-
level cardiac damage not detected by measures of ejec-
tion fraction ought to be included when investigating
the prognostic influence by ventricular ectopy.
Conclusions
In this study we demonstrate that the level of NT-
proBNP is independently associated with frequent PVCs
and complex ventricular ectopy, although none of the
biomarkers examined are specific biomarkers of asymp-
tomatic ventricular arrhythmias. We suggest that these
relationships points to underlying mechanisms, not
accounted for in traditional CV risk factors, which may
contribute to the association between these biomarkers
and CV death observed in the general population.
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